potassium dobesilate: for topical treatment of actinic keratoses [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 23672329 |
| CHEMBL ID | 1707052 |
| SCHEMBL ID | 78223 |
| MeSH ID | M0330897 |
| Synonym |
|---|
| benzenesulfonic acid, 2,5-dihydroxy-, monopotassium salt |
| c6h5ko5s |
| 21799-87-1 |
| hydroquinonesulfonic acid potassium salt, technical grade |
| MLS001333260 |
| smr000875261 |
| hydroquinonesulfonic acid potassium salt |
| MLS001333259 |
| potassium 2,5-dihydroxybenzenesulfonate |
| 2,5-dihydroxybenzenesulfonic acid potassium salt |
| potassium hydroquinonesulfonate |
| H0593 |
| dtxcid6024410 |
| cas-21799-87-1 |
| tox21_302096 |
| dtxsid8044410 , |
| NCGC00255728-01 |
| A815671 |
| HMS2234I14 |
| einecs 244-584-7 |
| potassium 2,5-dihydroxybenzenesulphonate |
| benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) |
| 249e3f00ep , |
| 2,5-dihydroxybenzenesulfonic acid, monopotassium salt |
| potassium dobesilate |
| unii-249e3f00ep |
| FT-0625555 |
| AKOS015889677 |
| SCHEMBL78223 |
| VKDSBABHIXQFKH-UHFFFAOYSA-M |
| W-107519 |
| CHEMBL1707052 |
| hydroquinone sulfonic acid, potassium salt |
| mfcd00007475 |
| potassium 2,5-dihydroxybenzene-1-sulfonate |
| AS-64019 |
| E76054 |
| potassium;2,5-dihydroxybenzenesulfonate |
| AMY8945 |
| Q27253834 |
| WAA79987 |
| hydroquinone sulfonic acid,potassium salt |
| CS-0157160 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 47.4436 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 26.8545 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.7186 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLS protein | Homo sapiens (human) | Potency | 3.9811 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 4.8966 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 3.1623 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 100.7150 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 2.0596 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| snurportin-1 | Homo sapiens (human) | Potency | 2.0596 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 31.3753 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 2.0596 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 7.3078 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 112.2020 | 6.3096 | 60.2008 | 112.2020 | AID720707 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein domain specific binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cortical actin cytoskeleton | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| microvillus | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| endomembrane system | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| lamellipodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| filopodium | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| extracellular exosome | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (30.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||